Alisa Lask - 18 Mar 2026 Form 3 Insider Report for CollPlant Biotechnologies Ltd (CLGN)

Reporting relationship: Director
Issuer ticker: CLGN
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 10:22:30 UTC
Prior SEC filing: 03 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Alisa Lask

Key filing fact

Alisa Lask filed Form 3 for CollPlant Biotechnologies Ltd (CLGN) on 18 Mar 2026.

Key facts

This page summarizes Alisa Lask's Form 3 filing for CollPlant Biotechnologies Ltd (CLGN).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Mar 2026, 10:22.

Change

Previous filing in this sequence was filed on 03 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001767593 Primary reporting owner

Lask Alisa

Relationship: Director
Address: C/O COLLPLANT BIOTECHNOLOGIES LTD., 4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK, REHOVOT, ISRAEL
Signature: /s/ Alisa Lask
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLGN holding

Restricted Share Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 10,000
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLGN holding Derivative

Options to Purchase Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 47,000
Exercise price: $6.39
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Of the restricted share units reported herein, 3,125 units are vested, and the remaining 6,875 units vest in eleven equal quarterly installments beginning March 25, 2026 and ending September 25, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

Footnote F2

44,062 options are fully vested and exercisable and the remaining 2,938 vest is May 2, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.